170.88
前日終値:
$171.55
開ける:
$169.77
24時間の取引高:
929.62K
Relative Volume:
0.77
時価総額:
$17.18B
収益:
$3.10B
当期純損益:
$668.60M
株価収益率:
26.27
EPS:
6.5044
ネットキャッシュフロー:
$831.30M
1週間 パフォーマンス:
-3.52%
1か月 パフォーマンス:
+7.47%
6か月 パフォーマンス:
+29.07%
1年 パフォーマンス:
+27.42%
Neurocrine Biosciences Inc Stock (NBIX) Company Profile
名前
Neurocrine Biosciences Inc
セクター
電話
(858) 617-7600
住所
6027 EDGEWOOD BEND COURT, SAN DIEGO, CA
Compare NBIX vs TAK, HLN, TEVA, ZTS, UTHR
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
|
NBIX
Neurocrine Biosciences Inc
|
170.88 | 17.25B | 3.10B | 668.60M | 831.30M | 6.5044 |
|
TAK
Takeda Pharmaceutical Co Adr
|
17.15 | 53.43B | 29.91B | 1.30B | 3.49B | 0.4056 |
|
HLN
Haleon Plc Adr
|
10.10 | 44.52B | 14.54B | 2.22B | 2.58B | 0.4871 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.03 | 37.52B | 17.53B | 1.58B | 444.18M | 1.3457 |
|
ZTS
Zoetis Inc
|
76.56 | 32.24B | 9.51B | 2.64B | 2.14B | 6.0361 |
|
UTHR
United Therapeutics Corp
|
535.67 | 22.46B | 3.17B | 1.29B | 1.01B | 27.09 |
Neurocrine Biosciences Inc Stock (NBIX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-02-24 | 開始されました | Wolfe Research | Outperform |
| 2026-01-08 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2025-10-21 | 開始されました | Citigroup | Buy |
| 2025-07-21 | 開始されました | Truist | Buy |
| 2025-07-10 | 開始されました | Goldman | Buy |
| 2025-04-15 | アップグレード | Needham | Hold → Buy |
| 2025-04-14 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-02-11 | 開始されました | Deutsche Bank | Hold |
| 2024-10-10 | 再開されました | Raymond James | Outperform |
| 2024-08-29 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2024-04-24 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2023-12-13 | 再開されました | Citigroup | Neutral |
| 2023-12-12 | 開始されました | Deutsche Bank | Buy |
| 2023-10-24 | 再開されました | Cantor Fitzgerald | Overweight |
| 2023-08-21 | 繰り返されました | Mizuho | Neutral |
| 2023-07-24 | アップグレード | SVB Securities | Market Perform → Outperform |
| 2023-07-06 | アップグレード | BMO Capital Markets | Underperform → Market Perform |
| 2023-05-04 | アップグレード | Guggenheim | Neutral → Buy |
| 2023-03-30 | アップグレード | Canaccord Genuity | Hold → Buy |
| 2023-03-03 | アップグレード | Evercore ISI | In-line → Outperform |
| 2023-02-03 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2022-11-14 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2022-10-11 | 開始されました | UBS | Buy |
| 2022-09-26 | 開始されました | Wells Fargo | Equal Weight |
| 2022-06-06 | 再開されました | Jefferies | Buy |
| 2022-03-03 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2022-02-25 | アップグレード | Goldman | Neutral → Buy |
| 2022-01-18 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-11-19 | 開始されました | BMO Capital Markets | Underperform |
| 2021-11-17 | アップグレード | JP Morgan | Neutral → Overweight |
| 2021-10-14 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-23 | 再開されました | Needham | Hold |
| 2021-08-06 | ダウングレード | Canaccord Genuity | Buy → Hold |
| 2021-05-18 | 再開されました | Goldman | Neutral |
| 2021-05-06 | アップグレード | Barclays | Equal Weight → Overweight |
| 2021-02-02 | 開始されました | Raymond James | Outperform |
| 2020-09-30 | 開始されました | The Benchmark Company | Hold |
| 2020-08-04 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2020-06-29 | ダウングレード | Goldman | Buy → Neutral |
| 2020-06-09 | 開始されました | Wedbush | Outperform |
| 2020-03-06 | 開始されました | Citigroup | Buy |
| 2020-02-27 | 開始されました | Barclays | Equal Weight |
| 2020-02-24 | 開始されました | William Blair | Outperform |
| 2020-02-06 | 開始されました | Mizuho | Neutral |
| 2020-02-05 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-12-13 | ダウングレード | Credit Suisse | Outperform → Neutral |
| 2019-08-07 | 開始されました | RBC Capital Mkts | Outperform |
| 2019-07-16 | 開始されました | Oppenheimer | Outperform |
| 2019-06-05 | 開始されました | Guggenheim | Neutral |
| 2019-05-21 | 開始されました | Credit Suisse | Outperform |
| 2019-04-22 | アップグレード | JP Morgan | Neutral → Overweight |
| 2019-04-12 | 開始されました | Evercore ISI | Outperform |
| 2019-02-06 | 繰り返されました | BofA/Merrill | Buy |
| 2019-01-23 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2018-12-13 | 開始されました | Goldman | Buy |
| 2018-11-21 | 開始されました | Canaccord Genuity | Buy |
すべてを表示
Neurocrine Biosciences Inc (NBIX) 最新ニュース
Neurocrine Biosciences (NBIX) Stock Looks Reasonable At Today’s Price - simplywall.st
Is Neurocrine Biosciences (NBIX) Still Undervalued Or Does Its P E Leave Little Upside? - simplywall.st
NEUROCRINE BIOSCIENCES, INC. : WELLS FARGO RAISES TARGET PRICE TO $200 FROM $175 - Bitget
Price to sales forward of Neurocrine Biosciences, Inc. – NASDAQ:NBIX - TradingView
NBIX Maintained by Wells Fargo -- Price Target Raised to $200 - GuruFocus
Wells Fargo Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Raises Target Price to $200 - Moomoo
Should Strong Earnings Projections and Zacks Rank #1 Status Require Action From Neurocrine Biosciences (NBIX) Investors? - simplywall.st
Zacks.com featured highlights include NVIDIA, Neurocrine Biosciences and Ball - The Globe and Mail
Neurocrine Biosciences (NASDAQ:NBIX) Fits the Growth at a Reasonable Price Mold of Peter Lynch Screening - ChartMill
BofA Securities Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Announces Target Price $199 - Moomoo
Neurocrine Biosciences Inc (NBIX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Can Neurocrine (NBIX) Run Higher on Rising Earnings Estimates? - Yahoo Finance
Neurocrine Price Target Raised to $200.00/Share From $155.00 by Truist Securities - Moomoo
NBIX Maintained by BMO Capital -- Price Target Raised to $170 - GuruFocus
Form 4 Neurocrine Biosciences Inc For: 13 July By Investing.com - Investing.com Nigeria
Neurocrine Biosciences chief legal officer sells $1.79m in stock - Investing.com UK
Neurocrine Biosciences chief legal officer sells $1.79m in stock By Investing.com - Investing.com South Africa
[Form 4] NEUROCRINE BIOSCIENCES INC Insider Trading Activity - Stock Titan
Neurocrine Biosciences (NBIX) officer exercises options, sells 4,367 shares - Stock Titan
Truist Financial Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Announces Target Price $200 - Moomoo
Truist raises Neurocrine Bio stock price target on pipeline potential - Investing.com
Truist raises Neurocrine Bio stock price target on pipeline potential By Investing.com - Investing.com Nigeria
Wedbush Lifts Price Target on Neurocrine Biosciences to $185 From $176, Keeps Outperform Rating - Moomoo
Reasons why investors should consider betting on Neurocrine stock - MSN
Neurocrine Biosciences (NBIX) Posts Strong Q1 Results, Is More Upside Still Left? - simplywall.st
Neurocrine Biosciences Inc (NASDAQ:NBIX) Scores High in Affordable Growth Screen - ChartMill
NEUROCRINE BIOSCIENCES INC (NBIX) Stock Chart - ChartMill
Form 144 NEUROCRINE BIOSCIENCES For: 10 July By Investing.com - Investing.com South Africa
Form 144 NEUROCRINE BIOSCIENCES For: 10 July - Investing.com India
[144] NEUROCRINE BIOSCIENCES INC SEC Filing - Stock Titan
3 Reasons Why Growth Investors Shouldn't Overlook Neurocrine (NBIX) - Yahoo Finance
Neurocrine Shares Hit Highs on Sales Spike, Strong Pipeline - Yahoo Finance
Did Neurocrine’s (NBIX) CRENESSITY Push Into Infants Just Recast Its Rare-Disease Strategy? - simplywall.st
Neurocrine Biosciences Insider Sold Shares Worth $2,603,112, According to a Recent SEC Filing - Moomoo
Neurocrine Biosciences chief regulatory officer sells $2.6m stock By Investing.com - Investing.com India
Neurocrine Biosciences chief regulatory officer sells $2.6m stock - Investing.com
Form 4 Neurocrine Biosciences Inc For: 9 July By Investing.com - Investing.com South Africa
Neurocrine (NBIX) officer sells 14,571 shares under Rule 10b5-1 plan - Stock Titan
Form 144 NEUROCRINE BIOSCIENCES For: 9 July By Investing.com - Investing.com Nigeria
Neurocrine Biosciences Inc (NBIX) 財務データ
収益
当期純利益
現金流量
EPS
Neurocrine Biosciences Inc (NBIX) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Delaet Ingrid | Chief Regulatory Officer |
Jul 10 '26 |
Sale |
181.02 |
4,367 |
790,514 |
16,225 |
| Lippoldt Darin | Chief Legal Officer |
Jul 09 '26 |
Option Exercise |
81.49 |
10,000 |
814,900 |
64,729 |
| Lippoldt Darin | Chief Legal Officer |
Jul 09 '26 |
Sale |
179.60 |
10,000 |
1,796,014 |
54,729 |
大文字化:
|
ボリューム (24 時間):